Walleye Capital
XFOR icon

Walleye Capital’s X4 Pharmaceuticals XFOR Stock Holding History

Walleye Capital’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,586
Closed -$66.1K – 6071
2024
Q1 		$66.1K Buy
1,586
+599
+61% +$16.7K ﹤0.01% 4575
2023
Q4 		$24.8K Buy
+987
New +$24K ﹤0.01% 4436

Other funds holding XFOR

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Walleye Capital's XFOR Position: Q2 2024 in Review

Walleye Capital sold out of X4 Pharmaceuticals (XFOR) in Q2 2024, closing a stake of 1,586 shares — an estimated $66.1K sold.

Walleye Capital first reported a position in XFOR in Q4 2023 and held it in 2 quarters. The position peaked at $66.1K in Q1 2024. 98 funds tracked by Wall St. Rank hold XFOR as of Q2 2024.

  • Walleye Capital reported no remaining X4 Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Walleye Capital sold 1,586 X4 Pharmaceuticals shares in Q2 2024, an estimated $66.1K.
  • Walleye Capital first reported a position in X4 Pharmaceuticals in Q4 2023 and held it in 2 quarters.
  • Walleye Capital's X4 Pharmaceuticals position peaked at $66.1K in Q1 2024.
  • 98 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2024.

Based on Walleye Capital's 13F filing for Q2 2024, filed 14 Aug 2024.